All In Biotech

Investigational drug · Phase 3

Insuline glargine U100

Also called: reduced, titrated

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy, Diabetes Mellitus, Type 2.

Phase 3

Last checked: Nov 20, 2026Latest source record: May 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

1 still active

All registered trials

1

Any phase or sponsor naming "Insuline glargine U100"

First trial start

2020

Sep 28, 2020

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Insuline glargine U100", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Relapsed/Refractory Acute Myeloid Leukaemia
  • Myeloid Malignancy
  • Diabetes Mellitus, Type 2
  • Obesity

Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "Insuline glargine U100" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2,452,425 on PubMed

Also in development for Relapsed/Refractory Acute Myeloid Leukaemia

  • APG-2575lisaftoclaxPhase 310 trials

    Ascentage Pharma Group Inc. · CLL/SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

  • OlverembatinibPhase 34 trials

    Ascentage Pharma Group Inc. · Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed/Refractory Acute Myeloid Leukaemia

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.